AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02359071 — intervention group
Intervention type: OTHER
Intervention: handover duration, handover rate
Description: To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
Study NCT03822897 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: 35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy
Study NCT04828733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty
Description: Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.
Study NCT04828733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty
Description: Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.
Study NCT04828733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.
Description: Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
Study NCT04639466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IM in the non-dominant upper arm
Study NCT04639466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IM in the non-dominant upper arm
Study NCT04639466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Description: Given IM in the non-dominant upper arm
Study NCT04639466 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Description: Given IM in the non-dominant upper arm
Study NCT03822897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
Study NCT03559777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: closed sinus lifting by Osteotome
Description: * Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar.
Study NCT03559777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed sinus lifting by Densah bur
Description: * Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar.
Study NCT03368105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prevention of C. difficile infections using LP299v strain
Description: Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy.
Study NCT03368105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prevention of C. difficile infections using LP299v strain
Description: Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy.
Study NCT03880162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
Study NCT03880162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy-matched standard diet
Description: Energy-matched (30% deficit) standard diet (50% of carbohydrates)
Study NCT04589260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1058
Description: Study drug to be administered by oral inhalation
Study NCT04589260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered by oral inhalation
Study NCT04278456 — intervention group
Intervention type: BEHAVIORAL
Intervention: postpartum depression
Description: melatonin levels in c-sections with different anesthesia modalities.
Study NCT02803866 — intervention group
Intervention type: BEHAVIORAL
Intervention: Training program CAP-PREM
Description: 1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
Study NCT02708498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
Study NCT01558726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management (Strength-Based)
Description: To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
Study NCT01558726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment
Description: The usual treatment used for regular patients of CAPSad
Study NCT00505024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System
Description: Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
Study NCT00505024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptoms Report
Description: A report of severe symptoms will be sent to your doctor or nurse.
Study NCT03945084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy
Study NCT03945084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care
Description: In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment.
Study NCT03945084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment.
Study NCT04510493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab
Description: Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours
Study NCT04510493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
Study NCT02346409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS of the cerebellum
Description: tACS of the cerebellum
Study NCT02346409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS of the cerebellum
Description: tACS of the cerebellum
Study NCT01900015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
Study NCT01900015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
Study NCT03660527 — intervention group
Intervention type: OTHER
Intervention: Not refered
Description: No intervention was refered.
Study NCT00774826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CVP
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
Study NCT00774826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
Study NCT00774826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-FM
Description: Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
Study NCT01482091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
Study NCT01482091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
Study NCT02382419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carrageenan-containing gel
Description: Applied vaginally
Study NCT02382419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied vaginally
Study NCT02382419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00539838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Description: Oral repeating dose
Study NCT00539838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous repeating dose
Study NCT00539838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose
Study NCT00539838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study NCT03974230 — intervention group
Intervention type: OTHER
Intervention: Collection of datas
Description: Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
Study NCT03974230 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Blood sample will be performed (genetic analyses).
Study NCT00911300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fondaparinux
Description: Comparison of different drugs
Study NCT03974230 — intervention group
Intervention type: OTHER
Intervention: slit lamp examination
Description: Slit lamp examination will be performed.
Study NCT00880529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ON-Q bupivicaine administration
Description: continuous subcutaneous bupivicaine drip
Study NCT00880529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV opioid administration
Description: Patient controlled analgesia with IV narcotics
Study NCT00805792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
Study NCT02382419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02382419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02382419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03164304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: intravenous
Study NCT03164304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: intravenous
Study NCT00271362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Amputation rehabilitation exercise program
Description: participants will be physically exercised with a full array of exercise methodologies.
Study NCT00271362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteomyoplasty vs. routine long posterior flap
Description: participants enrolled randomly in one of two surgical procedures.
Study NCT05032391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)
Description: Three times orally in a volume of 2.5 ml (1 dose)
Study NCT00630409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800 mg IV day 1 and 8
Study NCT00630409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: 24 mg/m2 every 21 days IV
Study NCT05032391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three times orally in a volume of 2.5 ml (1 dose)
Study NCT02493829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AML Cell Vaccine
Study NCT04329273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sliding leg curl
Description: The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
Study NCT04329273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition
Study NCT04329273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition
Study NCT02600715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (BoNT)
Study NCT02600715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Onabotulinumtoxin A (BoNT)
Study NCT01707563 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: skin punch biopsy and molecular biology
Study NCT01707563 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fibroblast culture and molecular biology
Study NCT03332316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Dexamethasone injection
Study NCT02600715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belladonna
Description: Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
Study NCT02600715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
Study NCT02600715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to B\&O suppository
Study NCT02600715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active B&O suppository of belladonna
Description: belladonna 16.2mg and morphine 7.5mg
Study NCT01822886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin + Gemcitabine
Description: Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
Study NCT03332316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Hydrochloride Inj 2 mg/ml
Description: Ropivacaine injection
Study NCT01227863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxitrol®
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
Study NCT02037217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial MRgFUS System
Study NCT00917488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardization of allergenic extract (Gly. domesticus)
Description: Allergenic extract for cutaneous prick-test
Study NCT03405428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Allen test
Description: Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.